{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T00:02:42Z","timestamp":1759017762203,"version":"3.44.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.cpcardiol.2022.101551","type":"journal-article","created":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T02:45:25Z","timestamp":1671158725000},"page":"101551","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Incident Stroke Events in Clinical Trials of Antihypertensive Drugs in Cardiovascular Disease Patients: A Network Meta-analysis of Randomized Controlled Trials"],"prefix":"10.1016","volume":"48","author":[{"given":"Gang","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3576-1032","authenticated-orcid":false,"given":"Jichang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2022.101551_bib0001","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41572-019-0118-8","article-title":"Ischaemic stroke","volume":"5","author":"Campbell","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0002","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000506396","article-title":"Regional and country-specific burden of ischaemic stroke, intracerebral haemorrhage and subarachnoid haemorrhage: a systematic analysis of the global burden of disease study 2017","volume":"54","author":"Krishnamurthi","year":"2020","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0003","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1161\/CIR.0000000000000558","article-title":"Heart disease and stroke statistics-2018 update: a report from the american heart association","volume":"137","author":"Benjamin","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0004","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0005","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1161\/HYPERTENSIONAHA.116.08485","article-title":"Blood pressure reduction and secondary stroke prevention: a systematic review and metaregression analysis of randomized clinical trials","volume":"69","author":"Katsanos","year":"2017","journal-title":"Hypertension (Dallas, Tex : 1979)"},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5853\/jos.2020.02698","article-title":"Role of blood pressure management in stroke prevention: a systematic review and network meta-analysis of 93 randomized controlled trials","volume":"23","author":"Zhong","year":"2021","journal-title":"J Stroke"},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0007","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1161\/CIRCULATIONAHA.110.016337","article-title":"Blood pressure targets in subjects with type 2 diabetes mellitus\/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials","volume":"123","author":"Bangalore","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0008","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ijcard.2016.01.197","article-title":"Blood pressure lowering and stroke events in type 2 diabetes: A network meta-analysis of randomized controlled trials","volume":"208","author":"Xie","year":"2016","journal-title":"Int J Cardiol Heart Vasc"},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0009","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1001\/jama.292.18.2217","article-title":"Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial","volume":"292","author":"Nissen","year":"2004","journal-title":"Jama"},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0010","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(04)16980-8","article-title":"Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial","volume":"364","author":"Poole-Wilson","year":"2004","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0011","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1056\/NEJMoa1008816","article-title":"Irbesartan in patients with atrial fibrillation","volume":"364","author":"Yusuf","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0012","first-page":"n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ (Clinical research ed.)"},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0013","first-page":"l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ (Clinical research ed.)"},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0014","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ (Clinical research ed.)"},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0015","first-page":"821","article-title":"Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators","volume":"342","year":"1993","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0016","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1001\/jama.1983.03340200048027","article-title":"A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results","volume":"250","year":"1983","journal-title":"Jama"},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0017","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0018","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0019","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0020","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","article-title":"Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)","volume":"362","author":"Fox","year":"2003","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0021","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0022","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0735-1097(00)00736-1","article-title":"Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril","volume":"36","author":"MacMahon","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0023","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa042739","article-title":"Angiotensin-converting-enzyme inhibition in stable coronary artery disease","volume":"351","author":"Braunwald","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0024","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1161\/01.CIR.102.13.1503","article-title":"Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators","volume":"102","author":"Pitt","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0025","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Yusuf","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0026","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions","volume":"327","author":"Yusuf","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0027","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/eurheartj\/ehu504","article-title":"Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial","volume":"36","author":"Sakata","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0028","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1001\/jama.290.21.2805","article-title":"A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial","volume":"290","author":"Pepine","year":"2003","journal-title":"Jama"},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0029","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","article-title":"Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan","volume":"360","author":"Dickstein","year":"2002","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0030","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","article-title":"Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial\u2013the Losartan Heart Failure Survival Study ELITE II","volume":"355","author":"Pitt","year":"2000","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0031","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jchf.2013.04.004","article-title":"Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2)","volume":"1","author":"Packer","year":"2013","journal-title":"JACC. Heart Failure."},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0032","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S0002-9149(01)01461-8","article-title":"The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function","volume":"87","author":"Pitt","year":"2001","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0033","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jacc.2005.09.055","article-title":"The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT)","volume":"47","author":"McMurray","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0034","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/eurheartj\/ehp101","volume":"30","author":"Kasanuki","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0035","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1161\/CIRCULATIONAHA.106.685073","article-title":"Effects of angiotensin-converting enzyme inhibition in low-risk patients early after coronary artery bypass surgery","volume":"117","author":"Rouleau","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0036","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0037","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1161\/01.CIR.102.15.1748","article-title":"Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin\/Enalapril Coronary Atherosclerosis Trial (SCAT)","volume":"102","author":"Teo","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0038","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.amjcard.2015.10.012","article-title":"Should antihypertensive treatment recommendations differ in patients with and without coronary heart disease? (from the antihypertensive and lipid-lowering treatment to prevent heart attack trial [ALLHAT])","volume":"117","author":"Alderman","year":"2016","journal-title":"The Am J Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0039","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/oxfordjournals.eurheartj.a014695","article-title":"Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS)","volume":"17","author":"Rehnqvist","year":"1996","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0040","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1161\/01.CIR.103.13.1721","article-title":"Low-dose metoprolol CR\/XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS)","volume":"103","author":"Hedblad","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0041","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1291\/hypres.27.181","article-title":"Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial","volume":"27","author":"Yui","year":"2004","journal-title":"Hypertension Res : Official J Japanese Soc Hypertension"},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0042","first-page":"887","article-title":"Long term effects of nisoldipine on the progression of coronary atherosclerosis and the occurrence of clinical events: the NICOLE study","volume":"89","author":"Dens","year":"2003","journal-title":"Heart (British Cardiac Society)"},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0043","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1161\/01.CIR.0000039288.86470.DD","article-title":"Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial","volume":"106","author":"Zanchetti","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0044","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJMoa0801369","article-title":"Treatment of hypertension in patients 80 years of age or older","volume":"358","author":"Beckett","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0045","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1097\/MJT.0000000000000369","article-title":"Efficacy of Calcium Channel Blockers Versus Other Classes of Antihypertensive Medication in the Treatment of Hypertensive Patients With Previous Stroke and\/or Coronary Artery Disease: A Systematic Review and Meta-Analysis","volume":"24","author":"Jeffers","year":"2017","journal-title":"Am J Ther"},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0046","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40256-015-0129-0","article-title":"Long-term anti-hypertensive therapy and stroke prevention: a meta-analysis","volume":"15","author":"Mukete","year":"2015","journal-title":"Am J Cardiovasc Drugs : Drugs, Devices, and Other Interventions"},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0047","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1751-7176.2011.00513.x","article-title":"Calcium channel blockers","volume":"13","author":"Elliott","year":"2011","journal-title":"J Clin Hypertens (Greenwich, Conn.)"},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0048","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0049","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(01)06178-5","article-title":"Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack","volume":"358","year":"2001","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0050","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1093\/advances\/nmaa041","article-title":"Dietary approaches to stop hypertension (dash) diet and blood pressure reduction in adults with and without hypertension: a systematic review and meta-analysis of randomized controlled trials","volume":"11","author":"Filippou","year":"2020","journal-title":"Adv Nutr (Bethesda, Md.)"},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0051","article-title":"Stroke: Molecular mechanisms and therapies: Update on recent developments","author":"Shehjar","year":"2022","journal-title":"Neurochem Int"},{"key":"10.1016\/j.cpcardiol.2022.101551_bib0052","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2174\/1570159X17666190927113021","article-title":"Nimodipine reappraised: an old drug with a future","volume":"18","author":"Carlson","year":"2020","journal-title":"Curr Neuropharmacol"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280622004480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280622004480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:59:55Z","timestamp":1758938395000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280622004480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0146280622004480"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101551","relation":{},"ISSN":["0146-2806"],"issn-type":[{"type":"print","value":"0146-2806"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incident Stroke Events in Clinical Trials of Antihypertensive Drugs in Cardiovascular Disease Patients: A Network Meta-analysis of Randomized Controlled Trials","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101551","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}],"article-number":"101551"}}